Načítá se...

Radium-223 for the treatment of castration-resistant prostate cancer

The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: El-Amm, Joelle, Aragon-Ching, Jeanny B
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4445785/
https://ncbi.nlm.nih.gov/pubmed/26056474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S44291
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!